2020 - A Year Full Of Potentials, page-29

Thanks TTE for your thoughts. Wasn't aware of the acquisition sentiment with CYP compared to MSB. I can sense this too and at the same time remind myself that for a large enough $$$ figure a deal can be struck with anyone. I can nonetheless see the logic for a big pharmaceutical company to go ahead with a purchase of CYP at a slightly higher risk profile but on the significant lower end of cost (comparing to MSB success and valuation to date as well as monitoring in the next 6 months) before CYP would get as expensive as MSB. Time will tell. A disclaimer that I own shares in both camps as well and believe both companies has significant runway with CYP reward/risk being favourable in my reading of the existing situation. Going long on both nevertheless! I'll be a happy camper if I can get 5x on one and 10x on the other